The dynamic changes in the numbers and functions of CD8+T cells and NK cells in advanced ovarian cancer patients undergoing first line chemotherapy
- VernacularTitle:卵巢癌患者一线化疗后CD8~+T细胞和NK细胞数量及功能动态变化的研究
- Author:
Qinmei FENG
;
Wen DI
;
Xia WU
- Publication Type:Journal Article
- Keywords:
Ovarian cancer;
Chemotherapy;
CD8+T cell;
NK cell
- From:
Chinese Journal of Immunology
1985;0(01):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective:The purpose of this study is to investigate the dynamic changes in the numbers and functions of CD8+T cells and NK cells in patients with advanced ovarian cancer undergoing first line chemotherapy,so as to identify whether there was a "window period" of anti-tumor immune suppression reverse after chemotherapy.Methods:Peripheral blood samples from each ovarian cancer patient were obtained before (S0) and at day 5-7 (S1),day 12-14 (S2) and day 25-28 (S3) after chemotherapy in 13 patients.The numbers and proportions of CD3+,CD4+,CD8+ and nature killer (NK) cells were analyzed by flow cytometry technique.The percentages of specific IFN-?-secreting CD8+cells were also calculated after that peripheral lymphocytes had been stimulated with self tumor lysates.Cytotoxicity of NK cells against K562 cells was detected by LDH releasing assay.Results:The numbers of CD3+,CD4+,CD8+T cells and NK cells reduced to the lowest on S1.Compared to those of the control group,and the percentages of IFN-?-secreting CD8+ T cells were remarkably higher on S1,S2 and S3 when CD8+ T cells were stimulated with autologous tumor antigen,and the percentage of CD8+ IFN-?+ cell reached the highest on S2.No significant differences of NK cell cytotoxicity against K562 cells were found on S1,S2 and S3 compared to S0.Conclusion:Paclitaxel and carboplatin induce lymphopenia,which triggers the temporary immune reconstitution.During immune reconstitution the enhanced priming of CD8+T cell response by autologous tumor antigen is found while the function of NK cells does not change significantly.It probably turns out that the "window period" during immune reconstitution offers a best opportunity for cancer immunotherapy.
